Newsroom | 4594 results

HOUSTON--(BUSINESS WIRE)--For millions of people living with the long-term effects of traumatic brain injury (TBI), the prevailing belief has been that chronic neuroinflammation causes recovery to plateau over time, meaning correspondingly few long-range care options. New research published in the prestigious journal Brain, one of the world’s leading neurology journals, is challenging that assumption. “Our findings suggest that chronic neuroinflammation may be a treatable target, even years aft...

CHICAGO & MILPITAS, Calif.--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming the next generation of cell therapies, and Applied StemCell Corp. (ASC), a leader in induced pluripotent stem cell (iPSC) technology and genome engineering, today announced a strategic collaboration to help unlock the next generation of regenerative medicine. The collaboration will focus on evaluating ASC’s iPSC and hypoimmune cell lines using Syntax Bio’s proprietary Cellgorithm™ platform to advanc...

SOUTH SAN FRANCISCO, Calif. & LOS ANGELES & SAN DIEGO--(BUSINESS WIRE)--Biocom, the largest life science membership association representing companies across California and major life science markets, today released its 2026 Life Science Economic Impact Report, offering a comprehensive look at the economic impact, emerging trends and innovation powering one of the state’s most important industries.The report, produced in partnership with UC San Diego and HSBC Innovation Banking, highlights the c...

CHICAGO & ITASCA, Ill.--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming the next generation of cell therapies, and Ajinomoto Health & Nutrition North America, Inc. (AHN), a leader in amino acid science and cell culture innovation and part of Ajinomoto Group, today announced a collaboration to evaluate Ajinomoto Group’s StemFit™ stem cell culture products using Syntax Bio’s proprietary Cellgorithm™ platform. Through the collaboration, AHN is providing Syntax Bio with Ste...

CHICAGO--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced an expanded Series A and new appointments to its executive leadership team, board of directors and scientific advisory board. The expansion brings Syntax Bio’s Series A to $14.4 million and total funding to over $25 million. The expanded round builds on support from Astellas Venture Management, Illumina Ventures, DCVC Bio, Civilization Ventures, EGB Capital, Mansu...

PALO ALTO, Calif.--(BUSINESS WIRE)--Greenstone Biosciences, Inc. announces a collaboration with Intel Corp. (NASDAQ: INTC) to accelerate AI-enabled drug discovery using Greenstone’s large-scale, human biobank of induced pluripotent stem cells and Intel’s Edge AI advanced computing and AI infrastructure. Intel and Greenstone are working together to speed up the development of new medicines. The collaboration combines state-of-the-art human genetics and biology from Greenstone with Intel purpose-...

BEAUFORT, S.C.--(BUSINESS WIRE)--Since 1995, the number of U.S. citizens with PAD has approximately doubled from 11 million to over 22 million. PAD is extremely costly with a current economic burden of $352-$694 billion, accounting for 7%-13% of National Health Expenditures.“Although PAD prevalence exceeds that of heart disease and stroke, compared to these other cardiovascular diseases, PAD remains underappreciated. PAD is a significant source of morbidity and mortality, as well as a major caus...

WOOD DALE, Ill.--(BUSINESS WIRE)--PHC Corporation of North America (PHCNA), provider of PHCbi cell culture and sample preservation solutions across North America and Latin America, has introduced a new series of laboratory incubators featuring active hybrid humidification technology and enhanced contamination control. The new Cell-IQ® CO₂ incubator line is designed to deliver improved environmental stability for a wide range of cell culture applications. Maintaining precise and stable incubatio...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Prime Radiant Fund SLP SICAV-RAIF, a fund advised by Prime Radiant Partners, has made a $50 million growth equity investment in the company’s Series D financing, bringing the total Series D to $327 million. Prime Radiant joins a distinguished list of investors including ARK Invest, investment funds managed by BlackRock, Eclipse, T. Rowe Price Inves...

TOKYO--(BUSINESS WIRE)--Heartseed dosed the 1st patient in its trial of HS-005, the world's 1st catheter delivery of iPSC-derived cardiomyocyte spheroids for heart failure....